WASHINGTON - The U.S. Food and Drug Administration said it has approved a new formulation of Merck's cancer therapy Keytruda that can be administered under the skin, offering a more convenient version of the widely used cancer immunotherapy.

The latest announcement could provide added convenience and potentially improve a patient’s experience.

Keytruda Qlex gets FDA approval

The new version, called Keytruda Qlex, is an injection that can be administered in as little as a minute or two depending on dosage, compared to IV infusion that typically takes about 30 minutes.

The injection can also be administered by healthcare professionals in multiple settings, from an infusion center to a doctor’s office or a local community-based clinic.

In addition, this new version also offers a choice

See Full Page